Latest News

03-01-2012 Shareholder Update
03-01-2012 Phylogica Janssen collaboration
21-12-2011 Notice Under Section 708A
15-12-2011 Phylogica Share Placement Raises $2.15 Million
13-12-2011 Phylogica and Pfizer Complete First Stage Of Peptide Vaccine Collaboration
News archive

Welcome

Phylogica is a leading peptide drug discovery company that utilises proprietary Phylomer peptide libraries and screening methodologies to identify unique peptide drug candidates for its pharmaceutical and biotechnology partners.

Phylomer® libraries contain the world's largest and most structurally diverse array of natural peptides. These peptides, known as Phylome® peptides, are sourced from evolutionary diverse microbes and they represent a new class of biological therapeutics. Phylomer® peptides display exceptional structural stability, specificity and affinity thereby giving them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies. Read more

 

Downloads

© 2012 Phylogica    |    ABN 48 098 391 961    |    Privacy Statement
Last updated: 02-02-2012    |    Website by Harmonic New Media and College Hill Life Sciences